샘플 요청 목록

 카트 문의
시장보고서
상품코드
1786514

세계의 발기부전 치료제 시장

Erectile Dysfunction Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 287 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

발기부전 치료제 세계 시장은 2030년까지 89억 달러에 달할 전망

2024년에 57억 달러로 추정되는 발기부전 치료제 세계 시장은 2024년부터 2030년까지 CAGR 7.8%로 성장하여 2030년에는 89억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 비아그라는 CAGR 7.8%를 기록하며 분석 기간 종료시에는 24억 달러에 달할 것으로 예상됩니다. 시알리스 부문의 성장률은 분석 기간 동안 CAGR 7.7%로 추정됩니다.

미국 시장은 15억 달러로 추정, 중국은 CAGR 12.1%로 성장할 것으로 예측

미국의 발기부전 치료제 시장은 2024년에 15억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 19억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 12.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.9%와 7.4%로 예측됩니다. 유럽에서는 독일이 CAGR 5.1%로 성장할 것으로 예측됩니다.

세계의 발기부전 치료제 시장 - 주요 동향과 촉진요인 정리

발기부전 치료제의 발전은 어떻게 치료 결과를 개선하고 있는가?

발기부전(ED) 치료제 시장은 제약회사들이 더 효과적이고 오래 지속되며 부작용이 적은 치료제를 개발함에 따라 빠르게 발전하고 있습니다. 실데나필(비아그라), 타다라필(시알리스), 발데나필(레비트라)과 같은 기존의 포스포디에스터라아제 5형(PDE5) 억제제는 여전히 주요 치료 옵션이지만, 연구를 통해 효능이 향상되고 부작용이 적은 개량형 제제가 개발되고 있습니다. 구강붕해정, 설하 필름, 속효성 스프레이와 같은 새로운 약물전달 메커니즘은 환자의 순응도와 편의성을 향상시키고 있습니다.

PDE5 억제제 외에도 일산화질소 방출 화합물, Rho-키나아제 억제제, 멜라노코르틴 수용체 작용제 등의 연구로 ED 치료의 새로운 길이 열리고 있습니다. 또한, 타다라필의 저용량 매일 복용 요법은 발기부전과 전립선 비대증(BPH) 치료에 있어 두 가지 이점이 있어 인기를 끌고 있습니다. 의약품의 기술 혁신이 효과를 최적화하고 금기 사항을 최소화하면서 ED 치료 환경은 환자 중심의 솔루션으로 변화하고 있습니다.

재생의료는 ED 치료의 미래를 어떻게 바꿀 것인가?

재생의료는 일시적인 증상 완화가 아닌 장기적인 해결책을 제시할 수 있는 ED 치료의 게임 체인저로 부상하고 있습니다. 줄기세포 치료, 혈소판풍부혈장(PRP) 주사, 충격파 치료는 ED 환자의 조직 재생을 촉진하고, 혈류를 촉진하며, 신경 기능을 개선하는 능력에 대해 연구되고 있습니다. 이러한 치료법은 혈관 기능 장애 및 신경 손상과 같은 ED의 근본적인 원인을 표적으로 삼고 있으며, 중증 및 치료 저항성 환자에서 유망한 결과를 보이고 있습니다.

유전자 치료는 일산화질소 신호전달과 음경 조직 복구에 관여하는 유전자를 변형시켜 발기 기능을 회복시키는 것을 목표로 하는 또 다른 연구 분야입니다. 또한, AI를 활용한 신약개발의 부상으로 유전자 및 대사 프로파일에 기반한 맞춤형 치료법 개발이 가속화되고 있습니다. 재생 및 유전자 기반 치료법 연구가 진행됨에 따라 ED 치료는 일시적인 증상 관리에서 장기적인 성기능 회복으로 전환될 것으로 예상됩니다.

발기부전 치료제 시장의 성장을 촉진하는 주요 요인은 무엇인가?

발기부전 치료제 시장의 성장은 인구 고령화로 인한 발기부전 유병률 증가, 당뇨병 및 심혈관질환 사례 증가, 치료 옵션에 대한 인식 증가가 원동력이 되고 있습니다. 원격의료와 디지털 헬스 플랫폼의 확대로 ED 치료제가 보다 친숙해지고, 낙인이 줄어들고, 환자들이 조기 치료를 받으려는 경향이 있습니다.

또한, PDE5 억제제 제네릭 의약품의 도입으로 시장 침투가 확대되어 치료제가 보다 저렴한 가격으로 널리 보급될 수 있게 되었습니다. 또한, 소비자들이 부작용이 적은 대체요법을 찾으면서 천연소재나 허브를 이용한 ED 치료제에 대한 수요도 증가하고 있습니다. 의약품의 발전, 디지털 헬스케어, 환자 선호도가 지속적으로 업계를 형성하면서 발기부전 치료제 시장은 지속적인 성장과 혁신의 태세를 갖추고 있습니다.

부문

제품(비아그라, 시알리스, 레비트라/스탁신, 스텐드라/스페드라, 자이데나, 기타 의약품), 투여 경로(경구 투여 경로, 주사 투여 경로, 기타)

조사 대상 기업 사례

  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Dong-A Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Hims & Hers Health, Inc.
  • Lupin Limited
  • Mankind Pharma
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Ro(Roman)
  • S.K. Chemicals Co., Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.14

Global Erectile Dysfunction Drugs Market to Reach US$8.9 Billion by 2030

The global market for Erectile Dysfunction Drugs estimated at US$5.7 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Viagra, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Cialis segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 12.1% CAGR

The Erectile Dysfunction Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Erectile Dysfunction Drugs Market - Key Trends & Drivers Summarized

How Are Advancements in Erectile Dysfunction Drugs Improving Treatment Outcomes?

The erectile dysfunction (ED) drugs market is evolving rapidly as pharmaceutical companies develop more effective, longer-lasting, and side effect-reducing treatments. Traditional phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), remain the primary treatment options, but research is leading to improved formulations with enhanced efficacy and fewer adverse effects. Novel drug delivery mechanisms, including orally disintegrating tablets, sublingual films, and fast-acting sprays, are increasing patient compliance and convenience.

Beyond PDE5 inhibitors, research into nitric oxide-releasing compounds, Rho-kinase inhibitors, and melanocortin receptor agonists is opening new avenues for ED treatment. Additionally, low-dose daily regimens of tadalafil are gaining popularity for their dual benefits in treating ED and benign prostatic hyperplasia (BPH). As pharmaceutical innovations continue to optimize effectiveness and minimize contraindications, the landscape of ED treatment is shifting towards more patient-centric solutions.

How Is Regenerative Medicine Reshaping the Future of ED Treatment?

Regenerative medicine is emerging as a game-changer in ED treatment, offering potential long-term solutions rather than temporary symptomatic relief. Stem cell therapy, platelet-rich plasma (PRP) injections, and shockwave therapy are being investigated for their ability to promote tissue regeneration, enhance blood flow, and improve nerve function in patients with ED. These therapies target the underlying causes of ED, such as vascular dysfunction and nerve damage, providing promising results for patients with severe or treatment-resistant cases.

Gene therapy is another area of exploration, aiming to restore erectile function by modifying genes involved in nitric oxide signaling and penile tissue repair. Additionally, the rise of AI-driven drug discovery is accelerating the development of personalized treatments based on genetic and metabolic profiles. As research into regenerative and gene-based therapies advances, ED treatment is expected to transition from temporary symptom management to long-term restoration of sexual function.

What Are the Key Factors Driving Growth in the Erectile Dysfunction Drugs Market?

The growth in the erectile dysfunction drugs market is driven by the rising prevalence of ED due to aging populations, increasing cases of diabetes and cardiovascular diseases, and growing awareness of treatment options. The expansion of telemedicine and digital health platforms is making ED drugs more accessible, reducing stigma, and encouraging patients to seek early treatment.

The introduction of generic versions of PDE5 inhibitors has also expanded market penetration, making treatments more affordable and widely available. Additionally, the demand for natural and herbal ED supplements is increasing, as consumers seek alternative remedies with fewer side effects. As pharmaceutical advancements, digital healthcare, and patient preferences continue to shape the industry, the ED drugs market is poised for sustained growth and innovation.

SCOPE OF STUDY:

The report analyzes the Erectile Dysfunction Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena, Other Drugs); Administration Route (Oral Administration Route, Injectable Administration Route, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Dong-A Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Hims & Hers Health, Inc.
  • Lupin Limited
  • Mankind Pharma
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Ro (Roman)
  • S.K. Chemicals Co., Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Erectile Dysfunction Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Global Male Population Throws the Spotlight on Long-Term Demand for Erectile Dysfunction Drugs
    • Rising Awareness and Openness About Sexual Health Drives Market Penetration Across Emerging Markets
    • Expanding Digital Health Platforms and Telemedicine Services Spur Prescription Rates and Product Accessibility
    • Increasing Prevalence of Lifestyle Diseases Like Obesity and Diabetes Strengthens Business Case for ED Medications
    • Shifting Cultural Norms and Reduced Social Stigma Around ED Accelerates Demand in Traditionally Conservative Regions
    • Rising Consumer Preference for Oral Therapies Drives Adoption of PDE5 Inhibitors
    • Technological Advancements in Drug Delivery Systems Open New Avenues for Market Expansion
    • Strong Pipeline of Novel Molecules and Next-Gen ED Therapies Expands Future Addressable Market
    • Growing Focus on Male Wellness and Preventative Health Spurs Demand for ED Treatment Options
    • Increasing Incidence of Psychological and Stress-Related Erectile Dysfunction Propels Need for Integrated Treatment Solutions
    • Enhanced Access to Online Pharmacies and e-Commerce Channels Bolsters Drug Sales and Distribution Reach
    • Personalized Medicine and Genetic Profiling Strengthen the Case for Targeted ED Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Erectile Dysfunction Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Erectile Dysfunction Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viagra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viagra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viagra by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cialis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cialis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cialis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Levitra / Staxyn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Levitra / Staxyn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Levitra / Staxyn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Stendra / Spedra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Stendra / Spedra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Stendra / Spedra by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Zydena by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Zydena by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Zydena by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Injectable Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Erectile Dysfunction Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • INDIA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Erectile Dysfunction Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Erectile Dysfunction Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • AFRICA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제